REFERENCES:
(1) Bland J: Physiological oxidation: Reduction and its relationship to biological aging. Healthcomm Clinical Research.
(2) Cooper FPS P: Ethylenedeniamine-tetraacetic acid (E.D.T.A.). The Pharmaceutical J, 376-377, 1955.
(3) Aamoth HL, Butt FJ: Maintaining food quality with chelating agents. Annals New York Academy of Science, 88:526-531, 1960.
(4) Casdorph HR: EDTA chelation therapy, efficacy in arteriosclerotic heart disease. J Holistic Medicine, 3(1):3-59, 1981.
(5) Casdorph HR: EDTA chelation therapy II, efficacy in brain disorders. J Holistic Medicine, 3(2):101-117, 1981.
(6) Casdorph HR, Farr CH: EDTA chelation therapy III: Treatment of peripheral arterial
occlusion, an alternative to amputation. J Holistic Medicine, 5(1):3-15, 1983.
(7) McDonagh EW, Rudolph CJ, Cheraskin E: an oculocerebrovasculometric analysis of the improvement in arterial stenosis following EDTA chelation. J Holistic Medicine, 4(1):21-23, 1982.
(8) McDonagh EW, Rudolph CJ, Cheraskin E: Effect of EDTA chelation therapy plus multivitamin trace mineral supplementation upon vascular dynamics: Ankle/brachial doppler systolic blood pressure ratio. J Holistic Medicine, 7(1):16-22, 1985.
(9) McDonagh EW, Rudolph CJ, Cheraskin E: The clinical change in patients treated with EDTA chelation plus multivitamin/trace mineral supplementation. J Orthomolecular Psychiatry, 14:61-65, 1985.
(10) Olszewer, E, Carter JP: EDTA chelation therapy in chronic degenerative disease. Medical Hypothesis, 27:41-49, 1988.
(11) Rudolph CJ, McDonagh EW, Wussow, DG: The effect of intravenous ethylene diamine tetra acetic acid (EDTA) upon bone density levels. J Advancement Med, 1(2):79-85, 1988.
(12) Cranton EM, Frackelton JP: Current status of EDTA chelation therapy in occlusive arterial disease. J Holistic Medicine, 4:24-33, 1982.
(13) Kitchell JR, Palmon F, Aytan N, Meltzer LE: The treatment of coronary artery disease with disodium EDTA, a reappraisal. Am J Cardiol, 11:501-506, 1963.
(14) Halstead BW: The scientific basis of EDTA a chelation therapy. Colton, CA, Golden Quill Publishers, 1979.
(15) Cranton EM, Brecher A: Bypassing bypass: the new technique of chelation therapy, ed 2, Trout Dale, VA, Medex Publishers Inc, 1989.
(16) Gordon GF: Oral chelation with EDTA. J Holistic Medicine, 8(1):79-80, 1986.
(17) Cranton EM: The current status of EDTA chelation therapy, editorial. J Holistic Med, 7(1):3-7, 1987.
(18) Clarke NE, Clarke CN, Mosher RE: Treatment of angina pectoris with disodiumethylene diamine tetraacetic acid. Am J Med Sci, 232:654-666, 1956.
(19) Clarke NE Sr: Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol, 6:233-236, 1960.
(20) Meltzer LE, Ural ME, Kitchel JR: The treatment of coronary art Meltzer LE, Ural ME, Kitchel JR: The treatment of coronary artery disease with disodium EDTA, in Seven MJ, Johnson, LA (eds): Metal Binding in Medicine, Philadelphia, J.B. Lippincont Co, 132-156, 1960.
(21) Kitchell JR, Meltzer LE, Seven MJ: Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis, 3:338-349, 1961.
(22) Leipzig LJ, Boyle AJ, McCann DS: Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J Chronic Dis, 22:553-563, 1970.
(23) Lamar CP: Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc 1966; 14:272-293.
(24) Brucknerova O, Tulacek J: Chelates in the treatment of occlusive atherosclerosis. (Czech, Praha) Vnitr Lek 1972;19:729-735.
(25) Physicians’ Desk Reference. Oradell, NJ, Medical Economics Company, 1964, pp1203-1204. Physicians’ Desk Reference. Oradell, NJ, Medical Economics Company, 1975, p1542. Physicians’ Desk Reference. Oradell, NJ, Medical Economics Company, 1982, p84.
(26) Gordon GB, Vance RB: EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopathic Annals, 4:38-62, 1976.
(27) Cranton EM, Brecher A: Bypassing bypass: the new technique of chelation therapy, Briarcliff Manor, NY, Stein and Day Publishers, Scarborough House, 1986.
(28) Sincock AM: Life extension in the rotifer Mytilina brevispina var redunca by the application of chelating agents, J Geront 30:289-293, 1975.
(29) Tyler A: Prolongation of life-span of sea urchin spermatozoa, and improvement of the fertilization-reaction, by treatment of spermatozoa and eggs with metal-chelating agents (amino acids, versene, DEDTC, oxine, cupron). Biol Bull 104:224, 1953.
(30) Tyler A: Longevity of gametes: histocompatibility – gene loss and neoplasia in aging and levels of biochemical organization (AM Bruder and GA Sacher, eds) Univ of Chicago Press, Sect 11, Part II:50-86, 1965.
(31) Balin A: Human biologic Age Determination. Boca Raton, Ann Arbor, London, Tokyo, CRC Press, 1994, Overview, p4.
(32) Williams D: Chemistry Dept, Springfield, IL, University of St. Andrews, St. Andrews, Scotland, Charles C. Thomas, Publisher, 1976, pp 380, 381, 387.
(33) Seven M Johnson L: Metal binding in medicine. Philadelphia, Montreal, Lippencott Company, 1960.
(34) Grier MT, Meyers DG: So much writing, so little science: a review of thirty-seven years of literature on edentate sodium chelation therapy. The Annuls of Pharmacotherapy, 27:1504-1509, 1993.
(35) Whitaker J: You have alternatives to bypass surgery. Health Healing Letter, 1993.
(36) Jones RJ: Chelation (Letter), JAMA, 250:72, 1983.
(37) Chaitlow L: Chelation Therapy: The revolutionary alternative to heart surgery, San Francisco, Thorsons, 1991.
(38) McDonagh EW: Chelation can cure: how to reverse heart disease, diabetes, stroke, high blood pressure. Kansas City, MO, Platinum Pen Publications, 1983.
(39) Chelation therapy of atherosclerosis. Drug Intell Clin Pharm, 18:1000-10003, 1984.
(40) Olwin JH and Koppel JL: Proc Soc Exp Biol Med 128:1137-1140, 1968 (5) CV Arterio 1.9.
(41) Patterson CC: Contaminated and natural lead environments of man. Arch Environ Health. 11:344, 1965.
(42) Lead: airborne lead in perspective. National Research Council-National Academy of Sciences, Washington, DC, 1972.
(43) Goyer RA and Rhynbe BC: Pathological effects of lead. Internat Rev Pathol, 12:1, 1973.
(44) Goyer RA, Chisolm JJ. Lead. Ch# in: Metallic Contaminants and Human Health. Duglas HK Lee, ed. New York, Academic Press, 1972.
(45) Murozumi M, et al: Chemical concentrations of pullutant lead aerosols, terrestrial dusts, and sea salts in Greenland and Antarctic snow strata. Geochem Cosmochim Acta. 33:1247, 1969.
(46) Six KM and Goyer RA: Experimental enhancement of lead toxicity by low dietary calcium. J Lab Clin Med, 76:933, 1970.
(47) Quarterman J, et al: The influence of dietary calcium and phosphate on lead metabolism. Trace Substances in Environmental Health-VII. Delbert D. Hemphill, ed. St. Louis: University of Missouri Press, 1973, p347.
(48) Kopito L, et al: Chronic plumbism in children. JAMA. 209(2), 1969.
(49) Jackson R: Secondhand smoke raises stroke chances: The Arizona Republic, pA10; as reported to Emma Ross of the Associated Press; 8/19/99.
(50) Casdorph HR, Walker M: Toxic metal syndrome: how metal poisonings can affect your brain: Garden City Park, NY, Avery Publishing Group, 1995.
(51) Halstead B, Scharffenberg RS: American Academy of Medical Preventics, EDTA Chelation Literature, Author and/or Subject Index. 1976. Research Department of Vitamin Research Products, Inc. Oral EDTA, a bibliography, Vitamin Research Products, Inc. 3579 Hwy 50 East, Carson City, NV 98701 (1-800-877-2447.
(52) Sugawara N, Sugawara C: Cadmium accumulation in organs and mortality during a continued oral uptake. Arch Toxicol. 32(4):297-306, 1974.
(53) Schroeder, HA: Renal cadmium and essential hypertension. JAMA, 187(5):359, 1964.
(54) Fox MRS: Effect of essential minerals on cadmium toxicity: A review. Food Science. #((2):321-324, 1974.
(55) Nordberg, GF: Effects of long-term cadmium exposure on the seminal vesicles of mice. J Reprod Fertil. 45(1):165-168, 1975.
(56) Schroder HA: The poisons around us. Bloomington, IN, Indiana Univeristy Press, 1974, 49.
(57) Rifat, SL, Eastwood MR, Crapper-McLaughlan DR, Corey PN: Effect of exposue of miners to aluminum powder. The Lancet 336:1162-65, 11/10/1990.
(58) Perl DP, Good PF: The association of aluminum, Alzheimer’s disease, and neurofibrillary tangles. J Neural Transm [Suppl] 24:205-211, 1987.
(59) Crapper-McLaughlan, DR, McLachlan DC, Krishnan B, Krishnan SS, Dalton AJ, Steele, JC: Aluminium and calcium in soil and food from Guam, Palau and Jamaica: implications for amyotrophic lateral sclerosis and Parkinsonism-dementia syndromes of Guam. Brain. 112:45-53, 1989.
(60) Bjorksten J: The crosslinkage theory or aging. J Amer Geriatrics Soc. 16(4):408-427, 1968.
(61) Pryor WA: Free radical reaction and their importance in biochemical systems. Fed Proc. 32:1862-1869, 1973.
(62) Demopoulos HB: the basis of free radical pathology. Fed Proc. 32:1859-1861, 1973.
(63) Demopoulos HB: Oxygen free radicals in central nervous system ischemia and trauma. Bull Europ Physiopath Resp. Resp.[Suppl] 17:127-155, 1982.
(64) Levine SA, Kidd PM: Antioxicant Adaption: Its role in Free Radical Pathology. San Leandro, CA: Allergy Research Group. 1985, pp 14-15.
(65) Crapper-McLachlan DR, Dalton AJ: Alterations in short-term retention, conditioned avoidance response acquisition and motivation following aluminimum-induced neuro-fibrillary degeneration. Physiology and Behaviour. 10:925-933, 1973.
(66) Crapper-McLachlan DR, Tomko GJ: Neuronal correlates of an encephalopathy associated with aluminum neurofibrillary degeneration. Brain Research 97:253-264, 1975.
(67) Crapper-McLachlan DR, DeBoni U: Aluminum in human brain disease—an overview. Neurotoxicology 1:3-16, 1980.
(68) Crapper-McLachlan DR, VanBerkum MFA: Aluminum: a role in degenerative brain disease associated with neurofibrillary degeneration. Progress in Brain Research. Vol 70; Swaab DF, Fliers E, Mirmiran M, VanGool, WA, VanHaaren F (Eds) Amsterdam, Elsevier Science Publishers, 1986, pp 399-409.
(69) Hamilton EI: Aluminum and Alzheimer’s disease—a comment. The Science of the Total Environment. 25:87-91, 1982.
(70) Lai JCK, Lim L, Davison AN: Differences in the inhibitory effect of Cd2+, MN2+ and aluminum 3+ on the uptake of dopamine by synaptosomes from forebrain and from striatum of the rat. Biochemical Pharmacology 30:3123-3125, 1981.
(71) Eggleston D, Nylander M: Correlation of dental amalgam with mercury in brain tissue. Research and Education. 56(6):704-707, Dec 1987.
(72) Nylander M, Friberg L, Lind B: Mercury concentrations in human brain and kidneys in relation to exposure from dental amalgam fillings. Swed Dent J. 11:179-187, 1987.
(73) Hemenway C: Amalgam declared dangerous. Dentistry Today. 2-10-89.
(74) Denton S: The mercury coverup. Health Consciousness Magazine. June 1989, pp 1-6.
(75) Clarkson TW, Friberg L, Hursh J, Nylander M: Biological Monitoring of Toxic Metals. New York City. Plenum Press, 1988.
(76) Hahn LJ, Kloiber R, Vimy MJ, et al: Dental ‘silver’ tooth fillings. A source of mercury exposure revealed by whole-body image scan and tissue analysis. FASEB J, 3:2641-2644, 1989.
(77) Bjorklund G: Mercury as a potential source for the etiology of Alzheimer’s disease. Trace Elements in Medicine. 8(4):208, 1991.
(78) Kahn Van N: Heavy metal poisoning: mercury and lead. Ann Init Med, 76:779-792, 1972.
(79) Nolan KR: Copper toxicity syndrome. J Orthomol Psychiatr. 12(4):270-82, 1983.
(80) Hoffman DO, Sverd JCJ, Voeller K: Lead and hyperactivity, behavioral response to chelation: A pilot study. AM J Psychiatry. 133:1155-58. 1976.
(81) Marlowe M, Folio R, Hall D, Errea J: Increased lead burdens and trace mineral status in mentally retarded children. J Spec Educ. 16:87-99, 1982.
(82) Marlowe M, Errera J, Stellern J, Beck D: Lead and mercury levels in emotionally disturbed children. J orthomol Psychiatr. 12(4):260-67, 1983.
(83) Erickson JE, Shirahata H, Patterson CC: Skeletal Concentrations of lead in ancient Peruvians. N Engl J Med. 300:946-51, 1979.
(84) Cranton E and Frackelton J: Free radical pathology in age-associated diseases: Treatment with EDTA chelation, nutrition and antioxidants. J of Holistic Medicine, 6(1)Spring/Summer:8-11, 1984.
(85) Peters HA: Trace minerals, chelating agents and the pophyrias. Fed Proc, (3)(Part II)(supp 10):227-34, 1961.
(86) Peripheral Flow Opened Up. Medical World News, Mar 15, 1963;4:36-39.
(87) Boyle AJ, Mosher RE, McCann DS: Some in vivo effects of chelation-I: Rheumatoid arthritis. J Chronic Dis. 16:325-28, 1963.
(88) Birk RE, Rupe CE: The treatment of systemic sclerosis with EDTA, pyridoxine and reserpine. Henry Ford Hospital Medical Bulletin. 14:109-39, June, 1966.
(89) Olwin JH, Koppel JL: Reduction of elevated plasma lipid levels in atherosclerosis following EDTA chelation therapy. Proc Soc Exp Biol Med, 128:1137-1139, 1968.
(90) Leipzig LJ, Boyle AJ, McCann DS: Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J Chronic Dis, 22:553-63, 1970.
(91) Carpenter DG: Correction of biological aging. Rejuvenation, 8:31-49, 1980.
(92) Wartman A, Lampe TX, McDann DS, boyle AJ: Plaque reversal with MgEDTA in experimental atherosclerosis: Elastin and collagen metabolism. J Atherso Res, 7:331, 1967.
(93) Clarke NE, Clarke CN, Mosher RE: The in vivo dissolution of metastatic calcium: An approach to atherosclerosis. Am J Med Sci, 229:142-149, 1955.
(94) Clarke NE, Clarke CN, Mosher RE: Treatment of angina pectoris and disodium ethylene diamine tetraacetic acid. Am J Med Sci, 232:654-66, 1956.
(95) Clarke NE Sr: Atherosclerosis, occlusive vascular disease and EDTA. AM J Cardiol, 6:233-236, 1960.
(96) American College of Advancement in Medicine. Protocol of the American college of advancement in medicine for the safe and effective administration of EDTA chelation therapy. 1989.
(97) American board of Chelation Therapy: Protocol for the intravenous administration of ethylene diamine tetraacetic acid (E.D.T.A.) in chelation therapy. Chicago, A.B.C.T, 1994.
(98) Sampliner J Buffington M Gordon GF: Plethysmography: A preliminary report of a new technique utilizing direct sphygm-ocuff pulsevolume recording. J International Academy of Preventive Medicine, Vol IV(2), Winter, 1977.
(99) Gordon GB Vance RB: EDTA chelation therapy for athersclerosis: history and mechanisms of action. Osteopathic Annals, 4:38-62, 1976. [Ice Man Studies]
(100) [Ice Man studies]
(101) Blumer W, Reich T: Leaded gasoline – a cause of cancer. Environmental International. 3:465-71, 1980.
(102) Olwin J Koppel JL: Reduction of elevated plasma lipid levels in atherosclerosis following EDTA thereapy. Proc Soc Exp Biol Med, (5)CV Arterio 1.9;128, 1968.
(103) Casdorf HR: EDTA chelation therapy II efficacy in brain disorders. J Holistic Medicine, 3(2):101-117, 1981.
(104) Bjorksten J, Yaeger LLS, Schenk RU: In vitro study of focused chelating techniques for metal-containing aggregates implicated in senile dementia. Rejuvenation VI, No.1, edited by LeCompte H, October 1978, pp. 73-75. (Paper presented at the XIth International Congress of Gerontology Tokyo, Japan, August 20-25, 1978.)
(105) Crapper-McLaughlan DR, DeBoni U: Alzheimer senile dementia: virus or metal? XIth International Congress of Gerontology, Abstracts for Plenary Sessions & Symposia, Tokyo, Japan, Aug 20-25, p45, 1978.
(106) Butt EM Nusbaum RE Gilmore TC Didio SL: Trace metal pattern in d MineraLab, Inc. A clinicians guide to toxic metals, sources-occupational exposures-signs and symptoms.
(107) Hayward, CA, MineraLab Inc, 1979.isease states: Metal Binding in Medicine (Seven M) Philadelphia, Montreal, J.B. Lippencott, 1960, pp 43-49.
(108) Cranton EM, Frackelton JP: Current status of EDTA chelation therapy in occlusive arterial disease. J Holistic Medicine. 4:24-33, 1982.
(109) Cook JD, Finch CA, Smith NJ: Evaluation of the iron status of a population. Blood, 48:449-55, 1967.
(110) Kannel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and the risk of cardiovascular disease. The Framingham Study. Ann Intern Med. 85:447-52, 1976.
(111) Hjortland MC, McNamara PM, Kannel WB: Some atherogenic concomitants of menopause: The Framingham Study. Am J Emidemiol. 103:304-11, 1976.
(112) Gordon T, Kannel WB, Hjortland MC, McNamara PM: Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 89:157-61, 1978.
OTHER REFERENCES
Bjorksten J: Longevity, a quest. Madison, WI, Bjorksten Research Foundation, 1981.
Chemical Society: Stability constants. Oxford, ENG, Alden & Mobray, Ltd, Alden Press (Special Publication 25) 1971.
Halstead B Rozema T: The Scientific basis of EDTA chelation therapy, Landrum, SC, TRC Publishing, 2d Ed, 1997.
Halstead B: Chelation therapy. Palm Desert, CA, (published in cooperation with) Ameri Acad Med Preventics, 1975.
Julian J: Chelation extends life. Hollywood, Wellness Press, 1981.
Olmstead SF Steward DK: Characterization of the patient population with coronary artery disease undergoing chelation therapy with disodium magnesium-ethylenediamine tetraacetate.
[Karl Note: Contrary to a lie by John Morgenthaler (here) repeated on the web, magnesium EDTA was widely used for IV chelation, as, for instance, reported in this study. This same study is referenced on the web of Dr. Garry F. Gordon -- Here.]
Reprints of Medical Literature on Chelation Therapy, 1978.
Sacramento Medical Preventics Clinic, Inc: Lead toxicity. Sacramento, December 1974.
Soffer A Chenoweth M Eichhorn GL Rosoff B Rubin M Spencer H: Chelation therapy. Springfield, IL, Charles C. Thomas Publishing, 1964.
U.S. Department of Health, Education, and Welfare (Public Health Service, National Institutes of Health): Symposium on development of iron chelators for clinical use. Bethesda, MD, DHEW Publication No. (NIH) 77-994, WF Anderson and MC Hiller, editors, 1975.
US Dept of Health, Education and Welfare: Increased lead absorption and lead poisoning in young children—A statement by the Center for Disease Control, USD of HEW pub #00-2629, March, 1975.
Walker M Trowbridge J: Chelation therapy-better health. Greenwich, Cn, Devin-Adair Publishing, 1965.
Walker M: The chelation way—The complete book of chelation therapy. Garden City Park, NY, Avery Publishing Group, Inc, 1990.
Walker M: The miracle healing power of chelation therapy—the intravenous and oral treatment for reversal and prevention of hardening of the arteries and other common degenerative diseases. Canfield, OH, Fischer Publishing, 1984.
Walter M Gordon GF: The chelation answer-How to prevent hardening of the arteries and rejuvenate your cardiovascular system. New York, M.Evans and Company, Inc., 1982.
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life. Check out our companion site, at: http://www.oralchelation.net where Karl's 2000 page book is published. Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION. His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.
